Chengda Pharmaceutical (301201.SZ): No orders in progress from the Pfizer API factory

Gelonghui, May 14 | Chengda Pharmaceutical (301201.SZ) said on the investor interactive platform that currently, the company has no orders from the Pfizer API factory. Please refer to the company's announcement for the information to be disclosed.

Gelonghui FinanceMay 14 04:18 ET

ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

ChengDa Pharmaceuticals (SZSE:301201) has had a great run on the share market with its stock up by a significant 32% over the last three months. As most would know, fundamentals are what usually gui

Simply Wall StMay 9 18:25 ET

Chengda Pharmaceutical (301201.SZ): one of the main suppliers of L-carnitine in the world

Gelonghui May 8 丨 Chengda Pharmaceutical (301201.SZ) said on the investor interactive platform that the company is one of the main suppliers of L-carnitine in the world. L-carnitine series products include medicinal grade and food/feed additives. The products that were reduced in the early stages were mainly the food/feed additive L-carnitine. Currently, the sales price market for related products has improved slightly, and there is still some uncertainty about the price trend of related products in the future.

Gelonghui FinanceMay 8 04:54 ET

Chengda Pharmaceutical (301201.SZ): Some products use synthetic biotechnology such as enzyme catalysis to improve the quality of related products and reduce production costs

Gelonghui, May 8, 丨 Chengda Pharmaceutical (301201.SZ) said on the investor interactive platform that some of the company's products use synthetic biotechnology such as enzyme catalysis to improve the quality of related products and reduce production costs. The company will then actively promote the application of enzyme catalysis technology and the upgrading of traditional catalytic technology to drive product process upgrading and quality improvement with new technology, providing more possibilities for future drug development. At the same time, the company invested in the establishment of Shanghai Chengjiutai Biomedical Co., Ltd. at the end of 2023, which will help the company lay out the biomedical sector and expand R&D, production and treatment business in the biological cell industry. In fact

Gelonghui FinanceMay 8 04:53 ET

Chengda Pharmaceutical (301201.SZ): 2.03% of shares have been repurchased

Gelonghui, May 7, 丨 Chengda Pharmaceutical (301201.SZ) announced that as of April 30, 2024, the company had repurchased a total of 3,137,500 shares of the company's shares through a dedicated securities account, accounting for 2.03% of the company's current total share capital. The highest transaction price was 22.21 yuan/share, the minimum transaction price was 14.63 yuan/share, and the total transaction amount was 55,266.67 million yuan (excluding transaction fees).

Gelonghui FinanceMay 7 04:13 ET

Chengda Pharmaceutical (301201.SZ) announced first-quarter results, net profit of 18.644,500 yuan, a decrease of 5.09%

According to the Zhitong Finance App, Chengda Pharmaceutical (301201.SZ) released its report for the first quarter of 2024. The company's revenue was 101 million yuan, a year-on-year decrease of 1.28%. Net profit attributable to shareholders of listed companies was 18.6445 million yuan, a year-on-year decrease of 5.09%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 10.2459 million, a year-on-year decrease of 26.77%. Basic earnings per share were $0.1215.

Zhitong FinanceApr 21 04:04 ET